首页> 外文期刊>Journal of Medicinal Chemistry >Rational Design of Bisubstrate-Type Analogues as Inhibitors of DNA Methyltransferases in Cancer Cells
【24h】

Rational Design of Bisubstrate-Type Analogues as Inhibitors of DNA Methyltransferases in Cancer Cells

机译:Bisupt型类似物的理性设计作为癌细胞中DNA甲基转移酶的抑制剂

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Aberrant DNA hypermethylation of promoter Of tumor suppressor genes is commonly observed in cancer, and its inhibition by small molecules is promising for their reactivation. Here we designed bisubstrate analogues-based inhibitors, by mimicking each substrate, the S-adenosyl-L-methionine and the deoxycytidine, and linking them together. This approach resulted in quinazoline quinoline derivatives as potent inhibitors of DNMT3A. and DNMT1, some showing certain isoform selectivity. We highlighted the importance of (i) the nature and rigidity of the linker between the two moieties for inhibition, as (ii) the presence of the nitrogen on the quinoline group, and (iii) of a hydrophobic group on the quinazoline. The most potent inhibitors induced demethylation of CDKN2A promoter in colon carcinoma HCT116 cells and its reactivation after 7 days of treatment. Furthermore, in a leukemia cell model system, we found a correlation between demethylation of the promoter induced by the treatment, chromatin opening at the promoter, and the reactivation of a reporter gene.
机译:在癌症中通常观察到肿瘤抑制基因启动子的异常DNA高甲基化,并且其小分子的抑制作为它们的再活化。在这里,我们通过模拟每个基材,S-腺苷-1-甲硫氨酸和脱氧胞苷,并将它们连接在一起,设计了基于基于基于基于类似的基于类似的抑制剂。这种方法导致喹唑啉喹啉衍生物作为DNMT3a的有效抑制剂。和DNMT1,一些显示某些同种型选择性。我们强调了(i)两部分部分之间的抑制作用之间的性质和刚度的重要性,如(ii)喹唑啉对喹啉基团的氮气的存在,以及(III)的存在。最有效的抑制剂在结肠癌HCT116细胞中诱导CDKN2A启动子的去甲基化及其在治疗7天后的再活化。此外,在白血病细胞模型系统中,我们发现通过治疗,染色蛋白在启动子处开口诱导的启动子的去甲基化与报告基因的再活化之间的相关性。

著录项

  • 来源
    《Journal of Medicinal Chemistry》 |2017年第11期|共15页
  • 作者单位

    CNRS Pierre Fabre USR3388 CRDPF Epigenet Targeting Canc ETaC 3 Ave H Curien F-31035 Toulouse 01 France;

    CNRS Pierre Fabre USR3388 CRDPF Epigenet Targeting Canc ETaC 3 Ave H Curien F-31035 Toulouse 01 France;

    CNRS Pierre Fabre USR3388 CRDPF Epigenet Targeting Canc ETaC 3 Ave H Curien F-31035 Toulouse 01 France;

    CNRS Pierre Fabre USR3388 CRDPF Epigenet Targeting Canc ETaC 3 Ave H Curien F-31035 Toulouse 01 France;

    CNRS Pierre Fabre USR3388 CRDPF Epigenet Targeting Canc ETaC 3 Ave H Curien F-31035 Toulouse 01 France;

    CNRS Pierre Fabre USR3388 CRDPF Epigenet Targeting Canc ETaC 3 Ave H Curien F-31035 Toulouse 01 France;

    Univ Lille CHU Lille INSERM UMR S1172 JPARC Jean Pierre Aubert Res Ctr IRCL F-59045 Lille France;

    Univ Lille CHU Lille INSERM UMR S1172 JPARC Jean Pierre Aubert Res Ctr IRCL F-59045 Lille France;

    CNRS Pierre Fabre USR3388 CRDPF Epigenet Targeting Canc ETaC 3 Ave H Curien F-31035 Toulouse 01 France;

    CNRS Pierre Fabre USR3388 CRDPF Epigenet Targeting Canc ETaC 3 Ave H Curien F-31035 Toulouse 01 France;

    CNRS Pierre Fabre USR3388 CRDPF Epigenet Targeting Canc ETaC 3 Ave H Curien F-31035 Toulouse 01 France;

    CNRS UMR 5099 LBME F-31062 Toulouse France;

    CNRS Pierre Fabre USR3388 CRDPF Epigenet Targeting Canc ETaC 3 Ave H Curien F-31035 Toulouse 01 France;

    CNRS Pierre Fabre USR3388 CRDPF Epigenet Targeting Canc ETaC 3 Ave H Curien F-31035 Toulouse 01 France;

    Univ Pierre &

    Marie Curie Paris 6 ENS CNRS Lab BioMol UMR 7203 4 Pl Jussieu F-75252 Paris 05 France;

    Conservatoire Natl Arts &

    Metiers CMGPCE EA7341 Lab Chim Mol 2 Rue Conte F-75003 Paris France;

    CNRS Pierre Fabre USR3388 CRDPF Epigenet Targeting Canc ETaC 3 Ave H Curien F-31035 Toulouse 01 France;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号